Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Total Liabilities: 2020-2024

Historic Total Liabilities for Autolus Therapeutics (AUTL) over the last 5 years, with Dec 2024 value amounting to $355.4 million.

  • Autolus Therapeutics' Total Liabilities rose 13.11% to $396.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $396.5 million, marking a year-over-year increase of 13.11%. This contributed to the annual value of $355.4 million for FY2024, which is 34.67% up from last year.
  • According to the latest figures from FY2024, Autolus Therapeutics' Total Liabilities is $355.4 million, which was up 34.67% from $263.9 million recorded in FY2023.
  • In the past 5 years, Autolus Therapeutics' Total Liabilities ranged from a high of $355.4 million in FY2024 and a low of -$210.0 million during FY2020.
  • Its 3-year average for Total Liabilities is $270.3 million, with a median of $263.9 million in 2023.
  • Data for Autolus Therapeutics' Total Liabilities shows a peak YoY skyrocketed of 143.92% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Autolus Therapeutics' Total Liabilities stood at -$210.0 million in 2020, then skyrocketed by 143.92% to $92.2 million in 2021, then skyrocketed by 107.72% to $191.6 million in 2022, then surged by 37.74% to $263.9 million in 2023, then surged by 34.67% to $355.4 million in 2024.